Centogene collaborates with Filgen Inc. Japan
Centogene AG, Germany, and Filgen Inc., are pleased to announce the start of a long-term exclusive partnership in Japan as of October 2015. The objective of this partnership is to provide better access to the highest quality genetic testing for rare hereditary disorders.
Filgen, Inc. was founded in 2004 at Nagoya, Japan. Filgen provides broad and cutting-edge analysis
services using microarray, mass spectrometer and next generation sequencing technology as a leading company of service providers of life-science field in Japan. The company also offers various RUO reagents and instruments, bioinformatics software as a distributor and provides self-developed products of nanoscience field.
CENTOGENE as the worldwide leader in the field of genetic diagnostic testing for rare hereditary diseases, with a broad test portfolio comprising more than 2,800 genes, has revolutionized clinical interpretation with highest medical quality.
Beyond utilizing existing knowledge to the benefit of all patients, this collaboration involves the partner’s commitment to bring the best care possible to all Japanese patients. This ensures that every patient is treated with the best individual care, based on quality-driven and fast results. Prof. Arndt Rolfs, CEO
CENTOGENE states: “We are so thrilled to intensify with this collaboration education and awareness
campaigns to support patients, physicians and healthcare systems in providing the best treatment”.
For more information, please visit www.filgen.jp